A targetable type III immune response with increase of IL-17A expressing CD4
Journal
Nature cancer
ISSN: 2662-1347
Titre abrégé: Nat Cancer
Pays: England
ID NLM: 101761119
Informations de publication
Date de publication:
29 Aug 2024
29 Aug 2024
Historique:
received:
01
12
2023
accepted:
18
07
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
aheadofprint
Résumé
Immune checkpoint inhibitors are standard-of-care for the treatment of advanced melanoma, but their use is limited by immune-related adverse events. Proteomic analyses and multiplex cytokine and chemokine assays from serum at baseline and at the adverse event onset indicated aberrant T cell activity with differential expression of type I and III immune signatures. This was in line with the finding of an increase in the proportion of CD4
Identifiants
pubmed: 39210005
doi: 10.1038/s43018-024-00810-4
pii: 10.1038/s43018-024-00810-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Schweizerische Akademie der Medizinischen Wissenschaften (Swiss Academy of Medical Sciences)
ID : YTCR 01/22
Informations de copyright
© 2024. The Author(s).
Références
Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974–1982 (2015).
pubmed: 25605845
pmcid: 4980573
doi: 10.1200/JCO.2014.59.4358
Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158–168 (2018).
pubmed: 29320654
doi: 10.1056/NEJMra1703481
Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
pubmed: 25891173
doi: 10.1056/NEJMoa1503093
Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
pubmed: 26027431
pmcid: 5698905
doi: 10.1056/NEJMoa1504030
Haanen, J. et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 1217–1238 (2022).
pubmed: 36270461
doi: 10.1016/j.annonc.2022.10.001
Schneider, B. J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 39, 4073–4126 (2021).
pubmed: 34724392
doi: 10.1200/JCO.21.01440
Ghisoni, E. et al. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy. Eur. J. Cancer 149, 153–164 (2021).
pubmed: 33865201
doi: 10.1016/j.ejca.2021.03.010
Wang, D. Y. et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 4, 1721–1728 (2018).
pubmed: 30242316
pmcid: 6440712
doi: 10.1001/jamaoncol.2018.3923
Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749–1755 (2016).
pubmed: 27806233
pmcid: 5247797
doi: 10.1056/NEJMoa1609214
Teulings, H. E. et al. Vitiligo-like depigmentation in patients with stage III–IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J. Clin. Oncol. 33, 773–781 (2015).
pubmed: 25605840
doi: 10.1200/JCO.2014.57.4756
Axelrod, M. L. et al. T cells specific for α-myosin drive immunotherapy-related myocarditis. Nature 611, 818–826 (2022).
pubmed: 36385524
pmcid: 9930174
doi: 10.1038/s41586-022-05432-3
Caturegli, P. et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am. J. Pathol. 186, 3225–3235 (2016).
pubmed: 27750046
pmcid: 5225294
doi: 10.1016/j.ajpath.2016.08.020
Iwama, S. et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl. Med. 6, 230ra245 (2014).
doi: 10.1126/scitranslmed.3008002
Sullivan, R. J. & Weber, J. S. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat. Rev. Drug Discov. 21, 495–508 (2022).
pubmed: 34316029
doi: 10.1038/s41573-021-00259-5
Das, R. et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J. Clin. Invest. 128, 715–720 (2018).
pubmed: 29309048
pmcid: 5785243
doi: 10.1172/JCI96798
Tuzlak, S. et al. Repositioning T
pubmed: 34545250
doi: 10.1038/s41590-021-01009-w
O’Connor, W. Jr. et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat. Immunol. 10, 603–609 (2009).
pubmed: 19448631
pmcid: 2709990
doi: 10.1038/ni.1736
Sonnenberg, G. F. et al. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J. Exp. Med. 207, 1293–1305 (2010).
pubmed: 20498020
pmcid: 2882840
doi: 10.1084/jem.20092054
Conti, H. R. et al. T
pubmed: 19204111
pmcid: 2646568
doi: 10.1084/jem.20081463
Hailemichael, Y. et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 40, 509–523.e6 (2022).
pubmed: 35537412
pmcid: 9221568
doi: 10.1016/j.ccell.2022.04.004
Tarhini, A. A. et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J. Immunother. Cancer 3, 39 (2015).
pubmed: 26380086
pmcid: 4570556
doi: 10.1186/s40425-015-0081-1
Dimitriou, F., Hogan, S., Menzies, A. M., Dummer, R. & Long, G. V. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. Eur. J. Cancer 157, 214–224 (2021).
pubmed: 34536945
doi: 10.1016/j.ejca.2021.08.031
Stroud, C. R. et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J. Oncol. Pharm. Pract. 25, 551–557 (2019).
pubmed: 29207939
doi: 10.1177/1078155217745144
Tokunaga, R. et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation—a target for novel cancer therapy. Cancer Treat. Rev. 63, 40–47 (2018).
pubmed: 29207310
doi: 10.1016/j.ctrv.2017.11.007
Yao, Z. et al. Human IL-17: a novel cytokine derived from T cells. J. Immunol. 155, 5483–5486 (1995).
pubmed: 7499828
doi: 10.4049/jimmunol.155.12.5483
Lodolce, J. P., Burkett, P. R., Koka, R. M., Boone, D. L. & Ma, A. Regulation of lymphoid homeostasis by interleukin-15. Cytokine Growth Factor Rev. 13, 429–439 (2002).
pubmed: 12401478
doi: 10.1016/S1359-6101(02)00029-1
Lamy, P. J. et al. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Breast Cancer Res. 13, R15 (2011).
pubmed: 21288332
pmcid: 3109584
doi: 10.1186/bcr2824
Kontos, F. et al. B7-H3: an attractive target for antibody-based immunotherapy. Clin. Cancer Res. 27, 1227–1235 (2021).
pubmed: 33051306
doi: 10.1158/1078-0432.CCR-20-2584
Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12, 180–190 (2012).
pubmed: 22343569
doi: 10.1038/nri3156
Borst, J., Hendriks, J. & Xiao, Y. CD27 and CD70 in T cell and B cell activation. Curr. Opin. Immunol. 17, 275–281 (2005).
pubmed: 15886117
doi: 10.1016/j.coi.2005.04.004
Hayette, S. et al. FLRG (follistatin-related gene), a new target of chromosomal rearrangement in malignant blood disorders. Oncogene 16, 2949–2954 (1998).
pubmed: 9671416
doi: 10.1038/sj.onc.1201807
Karsunky, H., Merad, M., Cozzio, A., Weissman, I. L. & Manz, M. G. Flt3 ligand regulates dendritic cell development from Flt3
pubmed: 12874263
pmcid: 2194067
doi: 10.1084/jem.20030323
Al-Obaide, M. A., Alobydi, H., Abdelsalam, A. G., Zhang, R. & Srivenugopal, K. S. Multifaceted roles of 5′-regulatory region of the cancer associated gene B4GALT1 and its comparison with the gene family. Int. J. Oncol. 47, 1393–1404 (2015).
pubmed: 26315939
doi: 10.3892/ijo.2015.3136
Maglione, D. et al. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 8, 925–931 (1993).
pubmed: 7681160
Platchek, M., Lu, Q., Tran, H. & Xie, W. Comparative analysis of multiple immunoassays for cytokine profiling in drug discovery. SLAS Discov. 25, 1197–1213 (2020).
pubmed: 32924773
doi: 10.1177/2472555220954389
Zweig, M. H. & Campbell, G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 39, 561–577 (1993).
pubmed: 8472349
doi: 10.1093/clinchem/39.4.561
Cui, W., Liu, Y., Weinstein, J. S., Craft, J. & Kaech, S. M. An interleukin-21–interleukin-10–STAT3 pathway is critical for functional maturation of memory CD8
pubmed: 22118527
pmcid: 3431922
doi: 10.1016/j.immuni.2011.09.017
Akitsu, A. & Iwakura, Y. Interleukin-17-producing γẟ T (γẟ17) cells in inflammatory diseases. Immunology 155, 418–426 (2018).
pubmed: 30133701
pmcid: 6231014
doi: 10.1111/imm.12993
Veldhoen, M. Interleukin 17 is a chief orchestrator of immunity. Nat. Immunol. 18, 612–621 (2017).
pubmed: 28518156
doi: 10.1038/ni.3742
Apalla, Z. et al. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement. J. Eur. Acad. Dermatol. Venereol. 36, 332–350 (2022).
pubmed: 34910332
doi: 10.1111/jdv.17855
Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019).
pubmed: 31562797
doi: 10.1056/NEJMoa1910836
Schnell, A. et al. Stem-like intestinal Th17 cells give rise to pathogenic effector T cells during autoimmunity. Cell 184, 6281–6298.e23 (2021).
pubmed: 34875227
pmcid: 8900676
doi: 10.1016/j.cell.2021.11.018
Hirota, K. et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat. Immunol. 12, 255–263 (2011).
pubmed: 21278737
pmcid: 3040235
doi: 10.1038/ni.1993
Nistala, K. et al. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc. Natl Acad. Sci. USA 107, 14751–14756 (2010).
pubmed: 20679229
pmcid: 2930428
doi: 10.1073/pnas.1003852107
Paroni, M. et al. Recognition of viral and self-antigens by T
pubmed: 28237728
doi: 10.1016/j.jaci.2016.11.045
Bamias, G. et al. Immunological characteristics of colitis associated with anti-CTLA-4 antibody therapy. Cancer Invest. 35, 443–455 (2017).
pubmed: 28548891
doi: 10.1080/07357907.2017.1324032
Callahan, M. K. et al. Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis. J. Clin. Oncol. 29, 2505–2505 (2011).
doi: 10.1200/jco.2011.29.15_suppl.2505
Reschke, R. et al. Checkpoint blockade-induced dermatitis and colitis are dominated by tissue-resident memory T cells and Th1/Tc1 cytokines. Cancer Immunol. Res. 10, 1167–1174 (2022).
pubmed: 35977003
pmcid: 9530647
doi: 10.1158/2326-6066.CIR-22-0362
Dulos, J. et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J. Immunother. 35, 169–178 (2012).
pubmed: 22306905
doi: 10.1097/CJI.0b013e318247a4e7
Papotto, P. H., Ribot, J. C. & Silva-Santos, B. IL-17
pubmed: 28518154
doi: 10.1038/ni.3726
Huber, M. et al. A Th17-like developmental process leads to CD8
pubmed: 19544308
doi: 10.1002/eji.200939412
Globig, A. M. et al. High-dimensional profiling reveals Tc17 cell enrichment in active Crohn’s disease and identifies a potentially targetable signature. Nat. Commun. 13, 3688 (2022).
pubmed: 35760777
pmcid: 9237103
doi: 10.1038/s41467-022-31229-z
Lim, S. Y. et al. Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy. Clin. Cancer Res. 25, 1557–1563 (2019).
pubmed: 30409824
doi: 10.1158/1078-0432.CCR-18-2795
Luoma, A. M. et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell 182, 655–671.e22 (2020).
pubmed: 32603654
pmcid: 7415717
doi: 10.1016/j.cell.2020.06.001
Groom, J. R. & Luster, A. D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 89, 207–215 (2011).
pubmed: 21221121
doi: 10.1038/icb.2010.158
Kisuya, J., Chemtai, A., Raballah, E., Keter, A. & Ouma, C. The diagnostic accuracy of Th1 (IFN-γ, TNF-α, and IL-2) and Th2 (IL-4, IL-6 and IL-10) cytokines response in AFB microscopy smear negative PTB- HIV co-infected patients. Sci. Rep. 9, 2966 (2019).
pubmed: 30814543
pmcid: 6393479
doi: 10.1038/s41598-019-39048-x
Parameswaran, N. & Patial, S. Tumor necrosis factor-α signaling in macrophages. Crit. Rev. Eukaryot. Gene Expr. 20, 87–103 (2010).
pubmed: 21133840
pmcid: 3066460
doi: 10.1615/CritRevEukarGeneExpr.v20.i2.10
Varaljai, R. et al. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nat. Cancer 4, 1292–1308 (2023).
pubmed: 37525015
pmcid: 10518254
doi: 10.1038/s43018-023-00610-2
Zhang, Y. et al. Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. J. Exp. Med. 217, e20190354 (2020).
pubmed: 32860704
pmcid: 7953739
doi: 10.1084/jem.20190354
Das, S. & Johnson, D. B. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J. Immunother. Cancer 7, 306 (2019).
pubmed: 31730012
pmcid: 6858629
doi: 10.1186/s40425-019-0805-8
Xing, P. et al. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J. Immunother. Cancer 7, 341 (2019).
pubmed: 31801636
pmcid: 6894272
doi: 10.1186/s40425-019-0779-6
Nunez, N. G. et al. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med 4, 113–129.e7 (2023).
pubmed: 36693381
doi: 10.1016/j.medj.2022.12.007
Stenken, J. A. & Poschenrieder, A. J. Bioanalytical chemistry of cytokines—a review. Anal. Chim. Acta 853, 95–115 (2015).
pubmed: 25467452
doi: 10.1016/j.aca.2014.10.009
Chen, G. et al. Th17 cell frequency and IL-17A production in peripheral blood of patients with non-small-cell lung cancer. J. Int. Med. Res. 48, 300060520925948 (2020).
pubmed: 32600079
Ozaki, K. & Leonard, W. J. Cytokine and cytokine receptor pleiotropy and redundancy. J. Biol. Chem. 277, 29355–29358 (2002).
pubmed: 12072446
doi: 10.1074/jbc.R200003200
Gershenwald, J. E. et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 67, 472–492 (2017).
pubmed: 29028110
pmcid: 5978683
doi: 10.3322/caac.21409
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
pubmed: 19097774
doi: 10.1016/j.ejca.2008.10.026
Bolton, J. et al. Multiplex serological assay for establishing serological profiles of polymorphic, closely related peptide antigens. MethodsX 8, 101345 (2021).
pubmed: 34430249
pmcid: 8374401
doi: 10.1016/j.mex.2021.101345
Assarsson, E. et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE 9, e95192 (2014).
pubmed: 24755770
pmcid: 3995906
doi: 10.1371/journal.pone.0095192
Dries, R. et al. Giotto: a toolbox for integrative analysis and visualization of spatial expression data. Genome Biol. 22, 78 (2021).
pubmed: 33685491
pmcid: 7938609
doi: 10.1186/s13059-021-02286-2
Germain, P. L., Lun, A., Garcia Meixide, C., Macnair, W. & Robinson, M. D. Doublet identification in single-cell sequencing data using scDblFinder. F1000Res 10, 979 (2021).
pubmed: 35814628
doi: 10.12688/f1000research.73600.1
Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573–3587.e29 (2021).
pubmed: 34062119
pmcid: 8238499
doi: 10.1016/j.cell.2021.04.048
Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163–172 (2019).
pubmed: 30643263
pmcid: 6340744
doi: 10.1038/s41590-018-0276-y
Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289–1296 (2019).
pubmed: 31740819
pmcid: 6884693
doi: 10.1038/s41592-019-0619-0